Clinical Practice Session
Implementation of Novel AKI Biomarkers in Clinical Practice
November 03, 2023 | 10:30 AM - 12:30 PM
Location: Ballroom B, Pennsylvania Convention Center
Session Description
Novel AKI biomarkers have been approved and implemented as diagnostic tests in clinical practice worldwide. This session describes clinicians' approaches to using these tests to prevent, assess, and manage AKI in clinical practice. They have used AKI biomarkers in different categories, alone or in combination, including kidney stress markers (e.g., TIMP2-IGFBP7); kidney damage markers (e.g., NGAL); kidney dysfunction markers (e.g., serum cystatin C, ultrasound); and US Food and Drug Administration- and European Medicines Agency-supported biomarker panels to detect drug-induced kidney injury during drug development.
Learning Objective(s)
- Discuss approaches to introducing novel AKI biomarkers for clinical use
- Specify the barriers to clinical implementation of novel AKI biomarkers in practice
- Describe approaches to the use of novel biomarkers to prevent, assess, and manage AKI in clinical practice
- Articulate approaches to clinical audit and continuous quality improvement processes related to the implementation of new AKI biomarkers in clinical practice
Learning Pathway(s)
- AKI and Critical Care
- Pharmacology
Moderators
Presentations
- How to Use Advanced Test Systems (TIMP2-IGFBP7) Testing in Clinical Practice
10:30 AM - 11:00 AM
- How to Use Neutrophil Gelatinase-Associated Lipocalin (NGAL) Testing in Clinical Practice
11:00 AM - 11:30 AM
- How to Use Functional AKI Biomarkers in Clinical Practice
11:30 AM - 12:00 PM
- How to Use Biomarkers of Drug-Induced Kidney Injury in Clinical Drug Development
12:00 PM - 12:30 PM